Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
| Autor: | Bingcao Wu, Frank Trudo, Jill Davis, Sally Hollis, Setareh A. Williams, Ozgur Tunceli, Charlie Strange, David M. Kern |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Budesonide medicine.medical_specialty Pharmaceutical Science Pharmacy Pulmonary Disease Chronic Obstructive 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Formoterol Fumarate Internal medicine medicine Humans 030212 general & internal medicine Intensive care medicine Adrenergic beta-2 Receptor Agonists Aged Retrospective Studies Fluticasone Asthma COPD business.industry Health Policy Health Care Costs Middle Aged Patient Acceptance of Health Care medicine.disease Fluticasone-Salmeterol Drug Combination United States Obstructive lung disease Bronchodilator Agents respiratory tract diseases 030228 respiratory system Budesonide/formoterol Drug Therapy Combination Female Formoterol Salmeterol business medicine.drug |
| Zdroj: | Journal of Managed Care & Specialty Pharmacy. 22:293-304 |
| ISSN: | 2376-1032 2376-0540 |
| DOI: | 10.18553/jmcp.2016.22.3.293 |
| Popis: | Chronic obstructive pulmonary disease (COPD) affects approximately 15 million people in the United States and accounts for approximately $36 billion in economic burden, primarily due to medical costs. To address the increasing clinical and economic burden, the Global Initiative for Chronic Obstructive Lung Disease emphasizes the use of therapies that help prevent COPD exacerbations, including inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA).To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system.COPD patients aged 40 years and older who initiated BFC (160/4.5 μg) or FSC (250/50 μg) treatment between March 1, 2009, and March 31, 2012, were identified using claims data from major U.S. health plans. BFC and FSC patients were propensity score matched (1:1) on age, sex, prior asthma diagnosis, prior COPD-related health care utilization, and respiratory medication use. COPD-related, pneumonia-related, and all-cause costs and utilization were analyzed during the 12-month follow-up period. Post-index costs were assessed with generalized linear models (GLMs) with gamma distribution. Health care utilization data were analyzed via logistic regression (any event vs. none) and GLMs with negative binomial distribution (number of visits) and were adjusted for the analogous pre-index variable as well as pre-index characteristics that remained imbalanced after matching.After matching, each cohort had 3,697 patients balanced on age (mean 64 years), sex (female 52% BFC and 54% FSC), asthma and other comorbid conditions, prior COPD-related health care utilization, and respiratory medication use. During the 12-month follow-up, COPD-related costs averaged $316 less for BFC versus FSC patients ($4,326 vs. $4,846; P = 0.003), reflecting lower inpatient ($966 vs. $1,202; P0.001), pharmacy ($1,482 vs. $1,609; P = 0.002), and outpatient/office ($1,378 vs. $1,436; P = 0.048) costs, but higher emergency department ($257 vs. $252; P = 0.033) costs. Pneumonia-related health care costs were also lower on average for BFC patients ($2,855 vs. $3,605; P0.001). Similarly, initiating BFC was associated with lower all-use health care costs versus initiating FSC ($21,580 vs. $24,483; P0.001, respectively). No differences in health care utilization were found between the 2 groups.In this study, although no difference was observed in rates of health care utilization, COPD patients initiating BFC treatment incurred lower average COPD-related, pneumonia-related, and all-cause costs versus FSC initiators, which was driven by cumulative differences in inpatient, outpatient, and pharmacy costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|